Adriana Arcila
Critical Care Medicine · Manati, PRNPI 1528269842
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,112 of the $1,522 with a category attached, or 73.0%. 9 manufacturers reported payments, led by Bayer at 26.3% of the total. 2025 is the largest year on record at $362, 3.2 times the $112 reported in 2019.
Across 43 payments — averaging $35.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$400
- GSK$287
- AstraZeneca$282
- Teva Pharmaceuticals USA, Inc.$246
- AbbVie$105
- Johnson & Johnson$84
- plus $118 from 3 others
What the payments were for
- Consulting fees$40026%
- Food & beverage$1,11273%
- Education$111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 2 | $400 |
| GSK | 20 | $287 |
| AstraZeneca | 12 | $282 |
| Teva Pharmaceuticals USA, Inc. | 2 | $246 |
| AbbVie | 1 | $105 |
| Johnson & Johnson | 1 | $84 |
| Boehringer Ingelheim | 3 | $74 |
| Sanofi | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,522 in reported general payments places this provider in the 65th percentile of 21 critical care medicine providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 360 | $255,677 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 396 | $199,884 |
| NucalaMepolizumab | 54 | $195,432 |
| Breo ElliptaFluticasone/Vilanterol | 455 | $189,464 |
| Fasenra PenBenralizumab | 33 | $189,007 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 160 | $104,234 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 130 | $62,474 |
| Spiriva RespimatTiotropium Bromide | 117 | $62,438 |
| Atrovent HfaIpratropium Bromide | 109 | $54,785 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 686 | $41,849 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 130 | $35,757 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 614 | $29,130 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 41 | $20,228 |
| Arnuity ElliptaFluticasone Furoate | 62 | $17,095 |
| Fluticasone Propionate | 793 | $12,228 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $287 | $720,1421,061 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $74 | $282,550554 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $282 | $112,591195 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 21 critical care medicine providers in Puerto Rico.
Other critical care medicine in Manati
- Christian Castillo LatorreSan Juan$35K
- Carlos Garcia RodriguezSan Juan$10K
- Gloria Rodriguez VegaBayamon$10K
- Daniel Font RiveraSan Juan$7K
- Axia Dones RodriguezCaguas$2K
- Jaime Aponte RodriguezSan Juan$2K
- Yomayra Otero-DominguezSan Juan$2K
- Ramon Paoli BrunoHumacao$1K
- Marta Rios-BenitezPonce$1K
- Claudia Cordoba CarrilloHato Rey$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.